AstraZeneca PLC said Monday that it has entered into an oncology partnership with Daiichi Sankyo Co. worth up to $6 billion that it stated might redefine treatment standards in lung, breast and multiple other cancers.
The British pharmaceutical giant stated it and Daiichi Sankyo will collectively develop and commercialize a new antibody drug conjugate, DS-1062, global, other than in Japan. The drug is presently in advancement, AstraZeneca stated.
Under the collaboration, AstraZeneca will pay Daiichi Sankyo an upfront payment of $1 billion in staged payments, it said. Extra conditional quantities of approximately $1 billion for the effective accomplishment of regulative approvals will be payable and up to $4 billion for sales-related milestones, AstraZeneca said.
” We now have 6 potential hits in Oncology with more to come in our early and late pipelines,” AstraZeneca President Pascal Soriot stated.
source https://jobsearchtips.net/astrazeneca-daiichi-sankyo-in-6b-oncology-offer/
No comments:
Post a Comment